Document and Entity Information
Document and Entity Information - shares | 3 Months Ended | |
Mar. 31, 2023 | May 15, 2023 | |
Document and Entity Information | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Mar. 31, 2023 | |
Document Transition Report | false | |
Entity File Number | 001-40929 | |
Entity Registrant Name | NEWCOURT ACQUISITION CORP | |
Entity Incorporation, State or Country Code | E9 | |
Entity Tax Identification Number | 00-0000000 | |
Entity Address, Address Line One | 2201 BroadwaySuite 705 | |
Entity Address, City or Town | Oakland | |
Entity Address State Or Province | CA | |
Entity Address, Postal Zip Code | 94612 | |
City Area Code | 510 | |
Local Phone Number | 214-3750 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | true | |
Entity Small Business | true | |
Entity Ex Transition Period | false | |
Entity Shell Company | true | |
Entity Central Index Key | 0001849475 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q1 | |
Amendment Flag | false | |
Transition Report | false | |
Redeemable warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units | ||
Document and Entity Information | ||
Title of 12(b) Security | Redeemable warrants, each exercisable for one Class A ordinary share for $11.50 per share, included as part of the units | |
Trading Symbol | NCACW | |
Security Exchange Name | NASDAQ | |
Class A ordinary shares | ||
Document and Entity Information | ||
Title of 12(b) Security | Class A ordinary shares, par value $0.0001 per share, included as part of the units | |
Trading Symbol | NCAC | |
Security Exchange Name | NASDAQ | |
Entity Common Stock, Shares Outstanding | 2,642,532 | |
Units, consisting of one Class A ordinary share, par value $0.0001 per share, and one redeemable warrant | ||
Document and Entity Information | ||
Title of 12(b) Security | Units, consisting of one Class A ordinary share, par value $0.0001 per share, and one redeemable warrant | |
Trading Symbol | NCACU | |
Security Exchange Name | NASDAQ | |
Class B ordinary shares | ||
Document and Entity Information | ||
Entity Common Stock, Shares Outstanding | 6,535,000 |
CONDENSED BALANCE SHEETS
CONDENSED BALANCE SHEETS - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
CURRENT ASSETS | ||
Cash | $ 15,957 | $ 128,678 |
Prepaid expenses | 211,743 | 248,224 |
Interest income receivable | 60,898 | 828,810 |
Total current assets | 288,598 | 1,205,712 |
LONG TERM ASSETS | ||
Investments held in Trust Account | 16,115,127 | 257,725,405 |
TOTAL ASSETS | 16,403,725 | 258,931,117 |
CURRENT LIABILITIES | ||
Accounts payable and accrued expenses | 632,503 | 417,712 |
Deferred underwriting fee payable | 13,100,000 | 13,100,000 |
Due to affiliate | 70,000 | 100,000 |
Loan from Sponsor | 685,000 | |
Derivative warrant liabilities | 392,100 | 653,500 |
Total current liabilities | 14,879,603 | 14,271,212 |
COMMITMENTS AND CONTINGENCIES | ||
SHAREHOLDERS' DEFICIT | ||
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding at March 31, 2023 and December 31, 2022 | ||
Accumulated deficit | (14,652,671) | (13,895,078) |
TOTAL SHAREHOLDERS' DEFICIT | (14,651,903) | (13,894,310) |
TOTAL LIABILITIES, REDEEMABLE ORDINARY SHARES AND SHAREHOLDERS' DEFICIT | 16,403,725 | 258,931,117 |
Class A ordinary shares | ||
SHAREHOLDERS' DEFICIT | ||
Common stock | 114 | 114 |
Class A ordinary shares subject to possible redemption | ||
REDEEMABLE ORDINARY SHARES | ||
Class A ordinary shares subject to possible redemption, $0.0001 par value, 1,502,532 and 25,000,000 shares at redemption value of $10.77 and $10.34 per share on March 31, 2023 and December 31, 2022 | 16,176,025 | 258,554,215 |
Class B ordinary shares | ||
SHAREHOLDERS' DEFICIT | ||
Common stock | $ 654 | $ 654 |
CONDENSED BALANCE SHEETS (Paren
CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares | Mar. 31, 2023 | Dec. 31, 2022 |
Preference shares, par value, (per share) | $ 0.0001 | $ 0.0001 |
Preference shares, shares authorized | 1,000,000 | 1,000,000 |
Preference shares, shares issued | 0 | 0 |
Preference shares, shares outstanding | 0 | 0 |
Class A ordinary shares | ||
Ordinary shares, par value, (per share) | $ 0.0001 | $ 0.0001 |
Common shares, shares authorized | 100,000,000 | 100,000,000 |
Class A ordinary shares subject to possible redemption | ||
Class A ordinary shares subject to possible redemption, (per share) | $ 0.0001 | $ 0.0001 |
Class A ordinary shares subject to possible redemption, shares outstanding | 1,502,532 | 25,000,000 |
Class A ordinary shares subject to possible redemption, redemption value (per share) | $ 10.77 | $ 10.34 |
Class A ordinary shares not subject to possible redemption | ||
Common shares, shares issued | 1,140,000 | 1,140,000 |
Ordinary shares, shares outstanding | 1,140,000 | 1,140,000 |
Class B ordinary shares | ||
Ordinary shares, par value, (per share) | $ 0.0001 | $ 0.0001 |
Common shares, shares authorized | 10,000,000 | 10,000,000 |
Common shares, shares issued | 6,535,000 | 6,535,000 |
Ordinary shares, shares outstanding | 6,535,000 | 6,535,000 |
CONDENSED STATEMENTS OF OPERATI
CONDENSED STATEMENTS OF OPERATIONS - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
OPERATING EXPENSES | ||
General and administrative | $ 771,493 | $ 326,902 |
Total operating expenses | 771,493 | 326,902 |
OTHER INCOME | ||
Interest income on investments held in Trust Account | 485,604 | 6,288 |
Change in fair value of warrants | 261,400 | 3,273,200 |
Total other income | 747,004 | 3,279,488 |
NET INCOME (LOSS) | $ (24,489) | $ 2,952,586 |
Class A ordinary shares | ||
OTHER INCOME | ||
Weighted average shares outstanding, basic | 4,896,611 | 22,000,000 |
Weighted average shares outstanding, diluted | 4,896,611 | 22,000,000 |
Basic net income (loss) per share | $ 0.15 | $ 0.10 |
Diluted net income (loss) per share | $ 0.15 | $ 0.10 |
Class B ordinary shares | ||
OTHER INCOME | ||
Weighted average shares outstanding, basic | 6,535,000 | 6,535,000 |
Weighted average shares outstanding, diluted | 6,535,000 | 6,535,000 |
Basic net income (loss) per share | $ 0 | $ 0.10 |
Diluted net income (loss) per share | $ 0 | $ 0.10 |
CONDENSED STATEMENTS OF CHANGES
CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT) - USD ($) | Class A ordinary shares | Class A ordinary shares not subject to possible redemption Ordinary shares | Class B ordinary shares Ordinary shares | Accumulated deficit | Total |
Balance at the beginning at Dec. 31, 2021 | $ 114 | $ 654 | $ (18,355,177) | $ (18,354,409) | |
Balance at the beginning (in shares) at Dec. 31, 2021 | 1,140,000 | 6,535,000 | |||
Increase (Decrease) in Stockholders' Equity | |||||
Net Income (loss) | 2,952,586 | 2,952,586 | |||
Balance at the end at Mar. 31, 2022 | $ 114 | $ 654 | (15,402,591) | (15,401,823) | |
Balance at the end (in shares) at Mar. 31, 2022 | 1,140,000 | 6,535,000 | |||
Balance at the beginning at Dec. 31, 2021 | $ 114 | $ 654 | (18,355,177) | (18,354,409) | |
Balance at the beginning (in shares) at Dec. 31, 2021 | 1,140,000 | 6,535,000 | |||
Balance at the end at Dec. 31, 2022 | $ 114 | $ 654 | (13,895,078) | (13,894,310) | |
Balance at the end (in shares) at Dec. 31, 2022 | 1,140,000 | 6,535,000 | |||
Increase (Decrease) in Stockholders' Equity | |||||
Accretion for Class A ordinary shares to redemption value | $ (733,104) | (733,104) | (733,104) | ||
Net Income (loss) | (24,489) | (24,489) | |||
Balance at the end at Mar. 31, 2023 | $ 114 | $ 654 | $ (14,652,671) | $ (14,651,903) | |
Balance at the end (in shares) at Mar. 31, 2023 | 1,140,000 | 6,535,000 |
CONDENSED STATEMENTS OF CASH FL
CONDENSED STATEMENTS OF CASH FLOWS - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES | ||
Net income (loss) | $ (24,489) | $ 2,952,586 |
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
Interest income on investments held in Trust Account | (1,253,516) | (6,288) |
Change in fair value of warrants | (261,400) | (3,273,200) |
Changes in operating assets and liabilities: | ||
Prepaid expenses | 36,481 | 36,554 |
Interest receivable | 767,912 | |
Due to affiliate | (30,000) | 20,000 |
Accounts payable and accrued expenses | 214,791 | 53,971 |
Net cash flows used in operating activities | (550,221) | (216,377) |
CASH FLOWS FROM INVESTING ACTIVITIES | ||
Cash deposited to Trust Account | (247,500) | |
Cash withdrawn from Trust account in connection with Class A ordinary shares redemption | 243,111,294 | |
Net cash flows provided by investing activities | 242,863,794 | |
CASH FLOWS FROM FINANCING ACTIVITIES | ||
Redemption of Class A ordinary shares | (243,111,294) | |
Advances from Sponsor | 685,000 | |
Net cash flows used in financing activities | (242,426,294) | |
NET CHANGE IN CASH | (112,721) | (216,377) |
CASH, BEGINNING OF PERIOD | 128,678 | 648,282 |
CASH, END OF PERIOD | 15,957 | 431,905 |
Supplemental disclosure of noncash activities: | ||
Accretion for Class A ordinary shares to redemption value | $ 733,104 | $ 1,253,516 |
Description of Organization and
Description of Organization and Business Operations | 3 Months Ended |
Mar. 31, 2023 | |
Description of Organization and Business Operations | |
Description of Organization and Business Operations | Note 1 – Description of Organization and Business Operations Newcourt Acquisition Corp. (the “Company” or “Newcourt”) was incorporated in the Cayman Islands on February 25, 2021. The Company is a blank check company formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or other similar business combination with one or more businesses or entities (the “Business Combination”). The Company is not limited to a particular industry or geographic region for purposes of consummating a Business Combination. The Company is an early stage and emerging growth company and, as such, the Company is subject to all of the risks associated with early stage and emerging growth companies. On January 9, 2023, the Company entered into a Business Combination Agreement (as amended by the amending agreement dated as of February 15, 2023, the “Business Combination Agreement”) with Newcourt SPAC Sponsor LLC, a Delaware limited liability company (the “Sponsor”), Psyence Group Inc., a corporation organized under the laws of Ontario, Canada (“Psyence”), and Psyence Biomed Corp., a corporation organized under the laws of British Columbia, Canada (“Psyence Biomed”). As of March 31, 2023, the Company had not commenced any operations. All activity through March 31, 2023, relates to the Company’s formation and Initial Public Offering (“IPO”), which is described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating income in the form of interest income earned on investments from the proceeds derived from the IPO. On October 22, 2021, the Company consummated the IPO of 22,000,000 units (“Units”) with respect to the Class A ordinary shares included in the Units being offered (the “Public Shares”) at $10.00 per Unit generating gross proceeds of $220,000,000, which is discussed in Note 3. The Company has selected December 31 as its fiscal year end. Pursuant to the Business Combination Agreement, subject to the terms and conditions set forth therein, at the Effective Time (as defined below), (a) a to-be-incorporated wholly-owned subsidiary of Psyence Biomed domiciled in the Cayman Islands (the “Merger Sub”) will be merged with and into Newcourt (the “Merger”), with Newcourt surviving the Merger as a direct wholly-owned subsidiary of Psyence Biomed (the “Combined Company”). As consideration for the Merger, as of the effective time of the Merger (the “Effective Time”) (i) each Class B ordinary share, par value $0.0001 per share, of Newcourt (the “Newcourt Class B Stock”), issued and outstanding immediately prior to the Effective Time, by virtue of the Merger and upon the terms set forth in the Business Combination Agreement, will be converted into the right to receive one common share of Psyence Biomed (each, a “Psyence Biomed Common Share”) (the “Per Share Merger Consideration”), and (ii) each Class A ordinary share, par value $0.0001 per share, of Newcourt (the “Newcourt Class A Stock”) issued and outstanding immediately prior to the Effective Time (after giving effect to the completion and payment of any redemptions of Newcourt Class A Stock (the “Redemption”)), other than shares owned by Newcourt, Merger Sub, Psyence Biomed or any of their respective subsidiaries, by virtue of the Merger and upon the terms and subject to the conditions set forth in the Business Combination Agreement, will be converted into the right to receive the Per Share Merger Consideration. The aggregate number of Psyence Biomed Common Shares into which the Newcourt Class A Stock and Newcourt Class B Stock are converted into is the merger consideration (the “Merger Consideration”). Before or upon the Closing, Psyence Biomed intends to transfer the shares of Good Psyence (Pty) Ltd (RF) (South Africa), Psyence Jamaica Ltd (Jamaica), Psyence UK Group Ltd., Psyence Therapeutics Corp. (Ontario, Canada), Mind Health (Pty) Ltd (Lesotho), Psyence South Africa (Pty) Ltd (South Africa), and Pure Psyence Corp. (Canada) to an entity of the Psyence’s choice. In connection with the transactions contemplated by the Business Combination Agreement (the “Transaction”), Newcourt and Psyence Biomed also intend to enter into Subscription Agreements with certain investors, prior to the consummation of the Transaction (the “Closing”), to provide financing to Newcourt, Psyence Biomed or the Combined Company (the “PIPE Investment”). Immediately prior to the consummation of the PIPE Investment, Psyence Biomed will effect a stock split, under which each Psyence Biomed Common Share that is issued and outstanding as of such time shall be split into a number of Psyence Biomed Common Shares determined by multiplying each such Psyence Biomed Common Share by a split factor, which is the quotient obtained by dividing the Per Share Psyence Biomed Value by $10.00. The “Per Share Psyence Biomed Value” is the quotient obtained by dividing $50,000,000 by the total number of issued and outstanding Psyence Biomed Common Shares immediately prior to the stock split. Simultaneously with the closing of the IPO, the Company consummated the sale of 1,080,000 units (“Private Placement Units”) at a price of $10.00 per Private Placement Unit in a private placement to the Company’s sponsor, Newcourt SPAC Sponsor LLC (the “Sponsor”) and underwriters Cantor Fitzgerald & Co. (“Cantor”), and Cohen & Company Capital Markets (“CCM”), generating gross proceeds of $10,800,000, which is described in Note 4. Offering costs for the IPO amounted to $15,937,545, consisting of $3,787,971 of underwriting fees, $11,000,000 of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $1,149,574 of other costs. Simultaneously with the closing of the IPO, the Company consummated the closing of the sale of 3,000,000 additional Units upon receiving notice of the underwriters’ election to partially exercise their over-allotment option (“Over-allotment Units”), generating additional gross proceeds of $30,000,000 and incurring additional offering costs of $2,100,000 in underwriting fees all of which is deferred until completion of the Company’s Business Combination. As described in Note 6, the $13,100,000 of deferred underwriting fee payable is contingent upon the consummation of a Business Combination by April 22, 2023, 18 months from the closing of the IPO, or for a further period of up to 3 months by July 22, 2023, 21 months from the closing of the IPO, subject to the terms of the underwriting agreement. Simultaneously with the exercise of the over-allotment, the Company consummated the Private Placement of an additional 60,000 Private Placement Units to the Sponsor, generating gross proceeds of $600,000. Following the closing of the IPO and exercise of the over-allotment, $255,000,000 ($10.20 per Unit) from the net proceeds of the sale of the Units in the IPO and the Private Placement Warrants was placed in a trust account (“Trust Account”) and will be invested in U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act of 1940, as amended (the “Investment Company Act”), with a maturity of 180 days or less or in any open-ended investment company that holds itself out as a money market fund selected by the Company meeting the conditions of paragraphs (d)(2), (d)(3) and (d)(4) of Rule 2a-7 of the Investment Company Act, as determined by the Company, until the earlier of: (i) the completion of a Business Combination and (ii) the distribution of the Trust Account, as described below. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the IPO and the sale of the Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the assets held in the Trust Account excluding the deferred underwriting commissions and taxes payable on income earned on the Trust Account at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act. There is no assurance the Company will be able to successfully effect a Business Combination. The Company will provide the holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially anticipated to be $10.20 per Public Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There will be no redemption rights with respect to the Company’s warrants. All of the Public Shares contain a redemption feature which allows for the redemption of such Public Shares in connection with the Company’s liquidation, if there is a shareholder vote or tender offer in connection with the Company’s Business Combination and in connection with certain amendments to the Company’s amended and restated memorandum and articles of association (as amended from time to time, the “Certificate of Incorporation”). In accordance with Accounting Standards Codification (“ASC”) 480-10-S99, redemption provisions not solely within the control of a company require Class A ordinary shares subject to redemption to be classified outside of permanent equity. Given that the Public Shares will be issued with other freestanding instruments (i.e., public warrants), the initial carrying value of Class A ordinary shares classified as temporary equity will be the allocated proceeds determined in accordance with ASC 470-20. The Class A ordinary shares are subject to ASC 480-10-S99. If it is probable that the equity instrument will become redeemable, the Company has the option to either (i) accrete changes in the redemption value over the period from the date of issuance (or from the date that it becomes probable that the instrument will become redeemable, if later) to the earliest redemption date of the instrument or (ii) recognize changes in the redemption value immediately as they occur and adjust the carrying amount of the instrument to equal the redemption value at the end of each reporting period. The Company has elected to recognize the changes immediately. While redemptions cannot cause the Company’s net tangible assets to fall below $5,000,001, the Public Shares are redeemable and are classified as such on the balance sheet until such date that a redemption event takes place. Redemptions of the Company’s Public Shares may be subject to the satisfaction of conditions, including minimum cash conditions, pursuant to an agreement relating to the Company’s Business Combination. If the Company seeks shareholder approval of the Business Combination, the Company will proceed with a Business Combination if a majority of the shares voted are voted in favor of the Business Combination, or such other vote as required by law or stock exchange rule. If a shareholder vote is not required by applicable law or stock exchange listing requirements and the Company does not decide to hold a shareholder vote for business or other reasons, the Company will, pursuant to its Certificate of Incorporation, conduct the redemptions pursuant to the tender offer rules of the Securities and Exchange Commission (the “SEC”) and file tender offer documents with the SEC prior to completing a Business Combination. If, however, shareholder approval of the transaction is required by applicable law or stock exchange listing requirements, or the Company decides to obtain shareholder approval for business or other reasons, the Company will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules and not pursuant to the tender offer rules. If the Company seeks shareholder approval in connection with a Business Combination, Sponsor has agreed to vote its Founder Shares (as defined in Note 5) and any Public Shares purchased during or after the IPO in favor of approving a Business Combination. Additionally, each Public Shareholder may elect to redeem their Public Shares without voting, and if they do vote, irrespective of whether they vote for or against the proposed transaction. Notwithstanding the foregoing, the Certificate of Incorporation provides that a Public Shareholder, together with any affiliate of such shareholder or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 15% or more of the Class A ordinary shares sold in the IPO, without the prior consent of the Company. The Company’s Sponsor, officers and directors (the “Initial Shareholders”) have agreed not to propose an amendment to the Certificate of Incorporation that would affect the substance or timing of the Company’s obligation to redeem 100% of its Public Shares if the Company does not complete a Business Combination, unless the Company provides the Public Shareholders with the opportunity to redeem their Class A ordinary shares in conjunction with any such amendment. On January 6, 2023, the Company’s shareholders approved an amendment (the “Extension Amendment”) to the amended and restated memorandum and articles of association to extend the date by which the Company must consummate an initial business combination for an initial three (3) months from January 22, 2023 to April 22, 2023 and up to three (3) times for an additional one (1) month each time from April 22, 2023 to July 22, 2023 (which is 21 months from the closing of our IPO). If the Company is unable to complete a Business Combination by July 22, 2023, the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten three The Initial Shareholders have agreed to waive their liquidation rights with respect to the Founder Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Shareholders should acquire Public Shares in or after the IPO, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to its deferred underwriting commission (see Note 6) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.20 per shares held in the Trust Account. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a vendor for services rendered or products sold to the Company, or a prospective target business with which the Company has discussed entering into a transaction agreement, reduce the amount of funds in the Trust Account. This liability will not apply with respect to any claims by a third party who executed a waiver of any right, title, interest or claim of any kind in or to any monies held in the Trust Account or to any claims under the Company’s indemnity of the underwriters of the IPO against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). Moreover, in the event that an executed waiver is deemed to be unenforceable against a third party, the Sponsor will not be responsible to the extent of any liability for such third-party claims. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers (except the Company’s independent registered public accounting firm), prospective target businesses or other entities with which the Company does business, execute agreements waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Liquidity and Capital Resources As of March 31, 2023, the Company had $15,957 in its operating bank accounts, $16,115,127 in securities held in the Trust Account to be used for a Business Combination or to repurchase or redeem its ordinary share in connection therewith and working capital deficit of $14,591,005. As of March 31, 2023, $485,604 of the amount on deposit in the Trust Account represented interest income, which is available to pay the Company’s tax obligations. Prior to the completion of the IPO, the Company lacked the liquidity it needed to sustain operations for a reasonable period of time, which is considered to be one year from the issuance date of the financial statement. The Company has since completed its IPO at which time capital in excess of the funds deposited in the Trust Account and/or used to fund offering expenses was released to the Company for general working capital purposes. Accordingly, management has since re-evaluated the Company’s liquidity and financial condition and determined that sufficient capital exists to sustain operations for at least one year from the date that the financial statement was issued, and therefore substantial doubt has been alleviated. In connection with the Company’s assessment of going concern considerations in accordance with the authoritative guidance in Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) No. 2014-15, “Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that the mandatory liquidation and subsequent dissolution described in the financial statements, should the Company be unable to complete a Business Combination, raises substantial doubt about the Company’s ability to continue as a going concern. If a Business Combination is not consummated by April 22, 2023, 18 months from the closing of the IPO, or for a further period of up to 3 months by July 22, 2023, 21 months from the closing of the IPO, there will be a mandatory liquidation and subsequent dissolution. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. It is uncertain that the Company will be able to consummate a Business Combination by the specified period. Also, in connection with the Company’s assessment of going concern considerations in accordance with ASU No. 2014-15 management has determined that if the Company is unable to raise additional funds to alleviate liquidity needs as well as complete a Business Combination by April 22, 2023, 18 months from the closing of the IPO, or for a further period of up to 3 months by July 22, 2023, 21 months from the closing of the IPO, then the Company will cease all operations except for the purpose of liquidating. The liquidity condition as well as the date for mandatory liquidation and subsequent dissolution raise substantial doubt about the Company’s ability to continue as a going concern. Recent events relating to the disruption in the U.S. banking system In March 2023, the shut‐down of certain financial institutions raised economic concerns over disruption in the U.S. banking system. The U.S. government took certain actions to strengthen public confidence in the U.S. banking system. However, there can be no certainty that the actions taken by the U.S. government will be effective in mitigating the effects of financial institution failures on the economy and restoring public confidence in the U.S. banking system. Additional financial institution failures may occur in the near term that may limit access to short‐term liquidity or have adverse impacts to the economy. Given the uncertainty of the situation, the related financial impact cannot be reasonably estimated at this time. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2023 | |
Summary of Significant Accounting Policies | |
Summary of Significant Accounting Policies | Note 2 — Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2023. The interim results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for any future periods. Emerging Growth Company The Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2023 and December 31, 2022. Investments Held in Trust Account At March 31, 2023 and December 31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. Interest receivable balance as at March 31, 2023 pertains to interest income on investments held in Trust and will be included in the investment balance when received by the Company. Interest income received is reinvested into the investments held in Trust account. Offering Costs associated with the IPO Offering costs, including additional underwriting fees associated with the underwriters’ exercise of the over-allotment option, consist principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable to the underwriters’ exercise of the over-allotment option in full, amounted to $18,037,545, consisting of $3,787,971 of underwriting fees, $13,100,000 of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $1,149,574 of other costs. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage and Securities Investor Protection Corporation Insurance coverage limits of $250,000 and $500,000 (including cash of $250,000 ). At March 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair Value of Financial Instruments The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: Income Taxes ASC Topic 740, Income taxes, prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of March 31, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States of America. As such, the Company’s tax provision was zero for the period presented. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and is measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, Class A ordinary shares is classified as stockholders’ equity. The Company’s Class A ordinary shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. On January 6, 2023, shareholders holding 23,497,468 ordinary shares exercised their right to redeem their shares for a pro rata portion of the funds in the Company’s Trust Account. Accordingly, on March 31, 2023, 1,502,532 shares of Class A ordinary shares subject to possible redemption is presented as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary share are affected by charges against additional paid in capital and accumulated deficit. At March 31, 2023, the Class A ordinary shares subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 250,000,000 Less: Proceeds allocated to Public Warrants (15,375,000) Class A ordinary share issuance costs (16,928,049) Plus: Accretion of carrying value to redemption value 37,303,049 Class A ordinary share subject to possible redemption as on December 31, 2021 255,000,000 Plus: Accretion of carrying value to redemption value 3,554,215 Class A ordinary share subject to possible redemption as on December 31, 2022 $ 258,554,215 Less : Redemption of ordinary shares (243,111,294) Plus: Accretion of carrying value to redemption value 733,104 Class A ordinary share subject to possible redemption as on March 31, 2023 $ 16,176,025 Net Income (loss) per Ordinary Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares (the “Founder Shares”). Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants (see Note 4) to purchase 13,070,000 Class A ordinary share at $11.50 per share were issued on October 22, 2021. At March 31, 2023 and December 31, 2022, no Public Warrants or Private Placement Warrants have been exercised. The 13,070,000 potential Class A ordinary shares for outstanding Public Warrants and Private Placement Warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three months ended March 31, 2023 and 2022 because they are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of stock. For the three months ended March 31, 2023 Basic and diluted net income (loss) per share: Class A ordinary share Class B ordinary share Numerator: Allocation of net loss before accretion income $ (10,490) $ (13,999) Accretion of Class A ordinary shares to redemption value 733,104 — Net income (loss) including accretion of Class A Redeemable shares to redemption value $ 722,614 $ (13,999) Denominator: Weighted average shares outstanding 4,896,611 6,535,000 Basic and diluted net income (loss) per share $ 0.15 $ (0.00) For the three months ended March 31, 2022 Basic and diluted net income per share: Class A ordinary share Class B ordinary share Numerator: Allocation of net income before accretion income $ 2,276,393 $ 676,193 Accretion of Class A ordinary shares to redemption value — — Net income including accretion of Class A Redeemable shares to redemption value $ 2,276,393 $ 676,193 Denominator: Weighted average shares outstanding 22,000,000 6,535,000 Basic and diluted net income per share $ 0.10 $ 0.10 Accounting for Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own common shares and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management has concluded that the Public Warrants and Private Placement Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment. Stock Compensation Expense In connection with the Company’s IPO, Founder Shares were sold to certain independent directors from among the Sponsor’s pool of Founder Shares at the price paid by the Sponsor (par value of $0.0001). Although these Founder Shares were purchased by the independent directors for value, under ASC 718, “Compensation – Stock Compensation,” these Founder Shares may be deemed stock-based compensation. The Company accounts for stock-based compensation expense in accordance with ASC 718, under which stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and recognized over the requisite service period. To the extent a stock-based award is subject to a performance condition, the amount of expense recorded in a given period, if any, reflects an assessment of the probability of achieving such performance condition, with compensation recognized once the event is deemed probable to occur. The fair value of equity awards has been estimated using a market approach. Forfeitures are recognized as incurred. As of October 6, 2021, the fair value of the 95,000 Founder Shares granted to certain independent directors by the Sponsor was $600,530 or $6.32 per share. The Company used a Monte Carlo Model simulation to arrive at the fair value of the stock compensation. The key assumptions in the option pricing model utilized are assumptions related to expected separation date of Units, anticipated business combination date, purchase price, share-price volatility, expected term, exercise date, risk-free interest rate and present value. The expected volatility as of the IPO closing date was derived based upon similar Special Purpose Acquisition Company (“SPAC”) warrants and technology exchange funds which with the Company’s stated industry target and terms until the exercise date. The Company’s Founder Shares sold to independent directors (see Note 5) was deemed within the scope of ASC 718 and are subject to a performance condition, namely the occurrence of a Business Combination. Compensation expense related to the 95,000 Founder Shares is recognized only when the performance condition is probable of occurrence, or more specifically when a Business Combination is consummated. Therefore, no stock-based compensation expense has been recognized for the three months ended March 31, 2023. Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement. |
Initial Public Offering
Initial Public Offering | 3 Months Ended |
Mar. 31, 2023 | |
Initial Public Offering | |
Initial Public Offering | Note 3 — Initial Public Offering Pursuant to the IPO, the Company sold 25,000,000 units (including 3,000,000 units as part of the underwriters’ partial exercise of the over-allotment option) at a price of $10.00 per Unit. Each Unit consists of one Class A ordinary share (such Class A ordinary shares included in the Units being offered, the “Public Shares”), and one |
Private Placement
Private Placement | 3 Months Ended |
Mar. 31, 2023 | |
Private Placement | |
Private Placement | Note 4 — Private Placement On October 22, 2021, simultaneously with the consummation of the IPO and the underwriters’ exercise of their over-allotment option, the Company consummated the issuance and sale (“Private Placement”) of 1,140,000 Units (the “Placement Units”) in a private placement transaction at a price of $10.00 per Placement Unit, generating gross proceeds of $11,400,000. The Placement Units were purchased by Cantor (187,000 Units), CCM (33,000 Units) and the Sponsor (920,000 Units). Each whole Private Placement Unit will consist of one Placement Share and one |
Related-Party Transactions
Related-Party Transactions | 3 Months Ended |
Mar. 31, 2023 | |
Related-Party Transactions | |
Related Party Transactions | Note 5 — Related Party Transactions Founder Shares On March 11, 2021, the Sponsor paid $25,000 to fund certain obligations of the Company in consideration for 5,912,500 Class B ordinary shares (the “Founder Shares”) of the Company par value $0.0001 (“Class B ordinary shares”) for an aggregate price of $25,000. In September 2021, the Company effected a dividend of approximately 0.017 shares for each Class B ordinary share outstanding, resulting in there being an aggregate of 6,015,000 Founder Shares outstanding. On October 19, 2021, the Company effected a dividend of approximately 0.099 shares for each outstanding Class B ordinary share, resulting in there being an aggregate of 6,611,500 Founder Shares outstanding. The Founder Shares will automatically convert into Class A ordinary shares at the time of the Company’s initial Business Combination and are subject to certain transfer restrictions, as described in Note 6. Holders of Founder Shares may also elect to convert their Class B ordinary shares into an equal number of Class A ordinary shares, subject to adjustment, at any time. The initial shareholders have agreed to forfeit up to 841,500 Founder Shares to the extent that the over-allotment option is not exercised in full by the underwriters. Since the underwriters exercised the over-allotment option only in part, the Sponsor did forfeit 76,500 Founder Shares. The Initial Shareholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of their Founder Shares until the earlier to occur of: (A) one year after the completion of the initial Business Combination or (B) subsequent to the initial Business Combination, (x) if the last sale price of the Class A ordinary shares equals or exceeds $12.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, or (y) the date on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the Company’s shareholders having the right to exchange their ordinary shares for cash, securities or other property. Related Party Loans On March 11, 2021, the Sponsor agreed to loan the Company an aggregate of up to $300,000 to cover expenses related to the IPO pursuant to a promissory note (the “2021 Note”). On June 21, 2021, the 2021 Note was increased to $1,000,000. This loan is non-interest bearing and payable on the earlier of March 31, 2023, or the expiration of the 45-day over-allotment option. The Company had no borrowings on the 2021 Note as of March 31, 2023. On January 6, 2023, the Company issued an unsecured promissory note in the amount of up to $495,000 to the Sponsor (the “Extension Loan”). This loan is non-interest bearing, non-convertible and payable on the consummation of the Company’s initial business combination. $247,500 is outstanding under this loan and shown under Loan from Sponsor as of March 31, 2023. On January 17, 2023, the Company issued an unsecured promissory note in the amount of up to $1,000,000 to the Sponsor (the “2023 Note”). This loan is non-interest bearing and payable on the consummation of the Company’s initial business combination. At maturity, the Sponsor may elect to convert any portion or all of the amount outstanding under the 2023 Note, up to a maximum of $1,000,000, into units of the entity surviving or resulting from the Initial Business Combination at a conversion price of $10.00 per unit. $437,500 is outstanding under this loan and shown under Loan from Sponsor as of March 31, 2023. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into units of the post Business Combination entity at a price of $10.00 per unit. The units would be identical to the Private Placement Units. As of March 31, 2023, there were no Working Capital Loans outstanding. Support Services The Company pays an affiliate of the Sponsor a fee of approximately $30,000 per month following the consummation of the IPO for office space, administrative and shared personnel support services. For the three months ended March 31, 2023 and for the period ended December 31, 2022, $60,000 and $220,000 was incurred respectively. $70,000 and $100,000 remains unpaid as of March 31, 2023 and December 31, 2022 respectively and is included on current liabilities in the balance sheet. For the three months ended March 31, 2023, an aggregate of $32,755 was paid to an entity related to the Chief Financial Officer for support services. |
Commitments and Contingencies
Commitments and Contingencies | 3 Months Ended |
Mar. 31, 2023 | |
Commitments and Contingencies | |
Commitments and Contingencies | Note 6 — Commitments and Contingencies Registration Rights The holders of Founder Shares, Private Placement Units and warrants that may be issued upon conversion of Working Capital Loans, if any, will be entitled to registration rights (in the case of the Founder Shares, only after conversion of such shares to Class A ordinary shares) pursuant to a registration rights agreement signed in connection with the IPO. These holders will be entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that the Company will not permit any registration statement filed under the Securities Act to become effective until the termination of the applicable lock-up period for the securities to be registered. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriters a 45-day option from the final prospectus relating to the IPO to purchase up to 3,300,000 additional Units to cover over-allotments, if any, at the IPO price less the underwriting discounts and commissions. On October 22, 2021, the underwriters elected to partially exercise the over-allotment option purchasing 3,000,000 units. The underwriters were paid a cash underwriting discount of $0.20 per unit net of reimbursements to the Company of $612,029 to pay for outside advisors, or $3,787,971 in the aggregate at the closing of the IPO. The underwriters have agreed to defer the cash underwriting discount of $0.20 per share related to the over-allotment to be paid at Business Combination ($600,000 in the aggregate). In addition, the underwriters are entitled to a deferred underwriting commissions of $0.50 per unit, or $12,500,000 from the closing of the IPO. The total deferred fee is $13,100,000, consisting of the $12,500,000 deferred portion and the $600,000 cash discount agreed to be deferred until Business Combination. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely if the Company completes a Business Combination, subject to the terms of the underwriting agreement. |
Shareholders' Deficit
Shareholders' Deficit | 3 Months Ended |
Mar. 31, 2023 | |
Shareholders' Deficit | |
Shareholders' Deficit | Note 7 — Shareholders’ Deficit Ordinary shares Class A ordinary shares— Class B ordinary shares— 45-day Holders of Class A ordinary shares and Class B ordinary shares will vote together as a single class on all other matters submitted to a vote of shareholders except as required by law. The Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the initial Business Combination on a one-for-one basis, subject to adjustment. In the case that additional Class A ordinary shares, or equity-linked securities, are issued or deemed issued in excess of the amounts offered in the IPO and related to the closing of the initial Business Combination,the ratio at which Class B ordinary shares shall convert into Class A ordinary shares will be adjusted (unless the holders of a majority of the outstanding Class B ordinary shares agree to waive such adjustment with respect to any such issuance or deemed issuance) so that the number of Class A ordinary shares issuable upon conversion of all Class B ordinary shares will equal, in the aggregate, on an as-converted basis, approximately 22.74% of the sum of the total number of all ordinary shares outstanding upon the completion of the IPO plus all Class A ordinary shares and equity-linked securities issued or deemed issued in connection with the initial Business Combination (excluding any shares or equity-linked securities issued, or to be issued, to any seller in the initial Business Combination and any private placement-equivalent warrants issued to the Sponsor or its affiliates upon conversion of loans made to the Company). Holders of Founder Shares may also elect to convert their Class B ordinary shares into an equal number of Class A ordinary shares, subject to adjustment as provided above, at any time. Preference Shares Warrants The Public Warrants will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation. Once the warrants become exercisable, the Company may redeem the Public Warrants: ● in whole and not in part; ● at a price of $0.01 per warrant; ● upon not less than 30 days ’ prior written notice of redemption; ● if, and only if, the reported last sale price of the Class A ordinary shares equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations and recapitalizations), for any 20 trading days within a 30 trading day period commencing at any time after the warrants become exercisable and ending on the third business day prior to the notice of redemption to warrant holders; and ● if, and only if, there is a current registration statement in effect with respect to the Class A ordinary shares underlying the warrants. If the Company calls the Public Warrants for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. The Private Placement Warrants are identical to the Public Warrants underlying the Units being sold in the IPO, except that the Private Placement Warrants and the Class A ordinary shares issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions. Additionally, the Private Placement Warrants are exercisable for cash or on a cashless basis, at the holder’s option, and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Placement Warrants. The exercise price and number of Class A ordinary shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a stock dividend, extraordinary dividend or the Company’s recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted for issuances of Class A ordinary shares at a price below their respective exercise prices. Additionally, in no event will the Company be required to net cash settle the warrants. If the Company is unable to complete a Business Combination within the Combination Period and the Company liquidates the funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly, the warrants may expire worthless. In addition, if the Company issues additional Class A ordinary shares or equity-linked securities for capital raising purposes in connection with the closing of a Business Combination at an issue price or effective issue price of less than $9.20 per Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the Company’s board of directors, and in the case of any such issuance to the Initial Shareholders or their affiliates, without taking into account any Founder Shares held by them prior to such issuance), (y) the aggregate gross proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of a Business Combination on the date of the consummation of a Business Combination (net of redemptions), and (z) the volume weighted average trading price of the Company’s Class A ordinary shares during the 20 trading day period starting on the trading day prior to the day on which the Company consummates a Business Combination (such price, the “Market Value”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the greater of (i) the Market Value or (ii) the price at which the Company issues the additional Class A ordinary shares or equity-linked securities. |
Fair Value Measurements
Fair Value Measurements | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Measurements | |
Fair Value Measurements | Note 8 — Fair Value Measurements The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Level 2: Level 3: At March 31, 2023 and December 31, 2022, there were 13,070,000 warrants outstanding (12,500,000 Public Warrants and 570,000 Private Placement Warrants). The following table presents information about the Company’s assets that are measured at fair value on a recurring basis at March 31, 2023 and December 31, 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. Quoted Significant Significant Prices Other Other in Active Observable Unobservable March 31, Markets Inputs Inputs Description 2023 (Level 1) (Level 2) (Level 3) Assets: Money Market Fund held in Trust Account $ 16,115,127 $ 16,115,127 — — Liabilities: Warrant Liability - Public Warrants $ 375,000 $ 375,000 — — Warrant Liability - Private Placement Warrants $ 17,100 — — $ 17,100 Quoted Significant Significant Prices Other Other in Active Observable Unobservable December 31, Markets Inputs Inputs Description 2022 (Level 1) (Level 2) (Level 3) Assets: Money Market Fund held in Trust Account $ 257,725,405 $ 257,725,405 — — Liabilities: Warrant Liability - Public Warrants $ 625,000 $ 625,000 — — Warrant Liability - Private Placement Warrants $ 28,500 — — $ 28,500 The Company utilizes a Black-Scholes simulation model to value the warrants at each reporting period, with changes in fair value recognized in the statement of operations. The estimated fair value of the warrant liability is determined using Level 3 inputs. Inherent in a Black-Scholes pricing model are assumptions related to expected share-price volatility, expected life, risk-free interest rate and dividend yield. The Company estimates the volatility of its ordinary shares based on industry historical volatility that matches the expected remaining life of the warrants. The risk-free interest rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of the warrants. The expected life of the warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is based on the historical rate, which the Company anticipates to remain at zero. The following table provides quantitative information regarding Level 3 fair value measurements at March 31, 2023 and December 31, 2022: March 31, 2023 December 31, 2022 Share Price $ 10.60 $ 10.28 Exercise Price $ 11.50 $ 11.50 Term (years) 5.31 5.62 Volatility 5.3 % 4.10 % Risk Free Rate 3.53 % 3.90 % Dividend Yield 0.00 % 0.00 % At March 31, 2023, the fair value of the Public Warrants and Private Placement Warrants was $0.03. At December 31, 2022, the fair value of the Public Warrants and Private Placement Warrants was $0.05. The following table presents the changes in the fair value of Level 3 warrant liabilities: Private Placement Warrants Fair value as of December 31, 2022 $ 28,500 Change in fair value (11,400) Fair value as of March 31, 2023 $ 17,100 There were no transfers in or out |
Subsequent Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2023 | |
Subsequent Events | |
Subsequent Events | Note 9 — Subsequent Events The Company has evaluated subsequent events through the date these financial statements were available for issuance and determined that other than the items disclosed below, there were no subsequent events that would require adjustment or disclosure: On April 3, 2023, the Company received a written notice (the “Letter”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5450(b)(2)(A), requiring the Company to maintain a Market Value of Listed Securities (“MVLS”) of $50,000,000 for the continued listing of its securities on The Nasdaq Global Market. The Letter is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the Company’s securities on Nasdaq. The Letter states that the Company has 180 calendar days, or until October 2, 2023, to regain compliance with Listing Rule 5450(b)(2)(A). If at any time during this compliance period the Company’s MLVS closes at $50,000,000 or more for a minimum of ten consecutive business days, Nasdaq will provide the Company with a written confirmation of compliance, and this matter will be closed. If compliance is not achieved by October 2, 2023, the Letter states that the Company will receive written notification that its securities are subject to delisting. At that time, the Company may appeal the delisting determination to a Hearings Panel. The Letter further notes that alternatively, the Company may be eligible to transfer the listing of its securities to The Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). The Company will continue to monitor its MVLS and consider its available options to regain compliance with the Nasdaq minimum MVLS requirements, but there can be no assurance that the Company will be able to do so. On April 19, 2023, the Sponsor deposited $82,500 into the Trust Account, on behalf of the Company, to extend the time available to the Company to consummate its initial business combination to May 22, 2023. |
Summary of Significant Accoun_2
Summary of Significant Accounting Policies (Policies) | 3 Months Ended |
Mar. 31, 2023 | |
Summary of Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X of the SEC. Certain information or footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments, consisting of a normal recurring nature, which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented. The accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC on March 23, 2023. The interim results for the period ended March 31, 2023 are not necessarily indicative of the results to be expected for any future periods. |
Emerging Growth Company | Emerging Growth Company The Company is an emerging growth company as defined in Section 102(b)(1) of the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), which exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period, which means that when a standard is issued or revised, and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates. |
Cash and Cash Equivalents | Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have any cash equivalents as of March 31, 2023 and December 31, 2022. |
Investments Held in Trust Account | Investments Held in Trust Account At March 31, 2023 and December 31, 2022, substantially all of the assets held in the Trust Account were held in U.S. Treasury securities. The Company’s investments held in the Trust Account are classified as trading securities. Trading securities are presented on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of investments held in Trust Account are included in interest earned on marketable securities held in Trust Account in the accompanying condensed statements of operations. The estimated fair values of investments held in Trust Account are determined using available market information. Interest receivable balance as at March 31, 2023 pertains to interest income on investments held in Trust and will be included in the investment balance when received by the Company. Interest income received is reinvested into the investments held in Trust account. |
Offering Costs Associated with the Initial Public Offering | Offering Costs associated with the IPO Offering costs, including additional underwriting fees associated with the underwriters’ exercise of the over-allotment option, consist principally of legal, accounting, underwriting fees and other costs directly related to the IPO. Offering costs, including those attributable to the underwriters’ exercise of the over-allotment option in full, amounted to $18,037,545, consisting of $3,787,971 of underwriting fees, $13,100,000 of deferred underwriting fees payable (which are held in the Trust Account (defined below)) and $1,149,574 of other costs. |
Concentration of Credit Risk | Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage and Securities Investor Protection Corporation Insurance coverage limits of $250,000 and $500,000 (including cash of $250,000 ). At March 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The fair value of the Company’s financial assets and liabilities reflects management’s estimate of amounts that the Company would have received in connection with the sale of the assets or paid in connection with the transfer of the liabilities in an orderly transaction between market participants at the measurement date. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from independent sources) and to minimize the use of unobservable inputs (internal assumptions about how market participants would price assets and liabilities). The following fair value hierarchy is used to classify assets and liabilities based on the observable inputs and unobservable inputs used in order to value the assets and liabilities: Level 1: Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis. Level 2: Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active. Level 3: |
Income Taxes | Income Taxes ASC Topic 740, Income taxes, prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. The Company’s management determined that the Cayman Islands is the Company’s major tax jurisdiction. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. As of March 31, 2023 and December 31, 2022, there were no unrecognized tax benefits and no amounts accrued for interest and penalties. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is considered to be an exempted Cayman Islands company with no connection to any other taxable jurisdiction and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States of America. As such, the Company’s tax provision was zero for the period presented. There is currently no taxation imposed on income by the Government of the Cayman Islands. In accordance with Cayman Islands income tax regulations, income taxes are not levied on the Company. Consequently, income taxes are not reflected in the Company’s financial statements. The Company’s management does not expect that the total amount of unrecognized tax benefits will materially change over the next twelve months. |
Class A Ordinary Share Subject to Possible Redemption | Class A Ordinary Shares Subject to Possible Redemption The Company accounts for its Class A ordinary shares subject to possible redemption in accordance with the guidance in ASC 480. Class A ordinary shares subject to mandatory redemption (if any) are classified as a liability instrument and is measured at fair value. Conditionally redeemable Class A ordinary shares (including Class A ordinary shares that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) is classified as temporary equity. At all other times, Class A ordinary shares is classified as stockholders’ equity. The Company’s Class A ordinary shares features certain redemption rights that are considered to be outside of the Company’s control and subject to occurrence of uncertain future events. On January 6, 2023, shareholders holding 23,497,468 ordinary shares exercised their right to redeem their shares for a pro rata portion of the funds in the Company’s Trust Account. Accordingly, on March 31, 2023, 1,502,532 shares of Class A ordinary shares subject to possible redemption is presented as temporary equity, outside of the stockholders’ deficit section of the Company’s condensed balance sheet. The Company recognizes changes in redemption value immediately as they occur and adjusts the carrying value of redeemable Class A ordinary share to equal the redemption value at the end of each reporting period. Increases or decreases in the carrying amount of redeemable ordinary share are affected by charges against additional paid in capital and accumulated deficit. At March 31, 2023, the Class A ordinary shares subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 250,000,000 Less: Proceeds allocated to Public Warrants (15,375,000) Class A ordinary share issuance costs (16,928,049) Plus: Accretion of carrying value to redemption value 37,303,049 Class A ordinary share subject to possible redemption as on December 31, 2021 255,000,000 Plus: Accretion of carrying value to redemption value 3,554,215 Class A ordinary share subject to possible redemption as on December 31, 2022 $ 258,554,215 Less : Redemption of ordinary shares (243,111,294) Plus: Accretion of carrying value to redemption value 733,104 Class A ordinary share subject to possible redemption as on March 31, 2023 $ 16,176,025 |
Net Income (loss) per Ordinary Share | Net Income (loss) per Ordinary Share The Company has two classes of shares, which are referred to as Class A ordinary shares and Class B ordinary shares (the “Founder Shares”). Earnings and losses are shared pro rata between the two classes of shares. Public Warrants (see Note 3) and Private Placement Warrants (see Note 4) to purchase 13,070,000 Class A ordinary share at $11.50 per share were issued on October 22, 2021. At March 31, 2023 and December 31, 2022, no Public Warrants or Private Placement Warrants have been exercised. The 13,070,000 potential Class A ordinary shares for outstanding Public Warrants and Private Placement Warrants to purchase the Company’s stock were excluded from diluted earnings per share for the three months ended March 31, 2023 and 2022 because they are contingently exercisable, and the contingencies have not yet been met. As a result, diluted net income per ordinary share is the same as basic net income per ordinary share for the period. The table below presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of stock. For the three months ended March 31, 2023 Basic and diluted net income (loss) per share: Class A ordinary share Class B ordinary share Numerator: Allocation of net loss before accretion income $ (10,490) $ (13,999) Accretion of Class A ordinary shares to redemption value 733,104 — Net income (loss) including accretion of Class A Redeemable shares to redemption value $ 722,614 $ (13,999) Denominator: Weighted average shares outstanding 4,896,611 6,535,000 Basic and diluted net income (loss) per share $ 0.15 $ (0.00) For the three months ended March 31, 2022 Basic and diluted net income per share: Class A ordinary share Class B ordinary share Numerator: Allocation of net income before accretion income $ 2,276,393 $ 676,193 Accretion of Class A ordinary shares to redemption value — — Net income including accretion of Class A Redeemable shares to redemption value $ 2,276,393 $ 676,193 Denominator: Weighted average shares outstanding 22,000,000 6,535,000 Basic and diluted net income per share $ 0.10 $ 0.10 |
Accounting for Warrants | Accounting for Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the instruments’ specific terms and applicable authoritative guidance in ASC 480 and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the instruments are free standing financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the instruments meet all of the requirements for equity classification under ASC 815, including whether the instruments are indexed to the Company’s own common shares and whether the instrument holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, was conducted at the time of warrant issuance and as of each subsequent period end date while the instruments are outstanding. Management has concluded that the Public Warrants and Private Placement Warrants issued pursuant to the warrant agreement qualify for equity accounting treatment. |
Stock Compensation Expense | Stock Compensation Expense In connection with the Company’s IPO, Founder Shares were sold to certain independent directors from among the Sponsor’s pool of Founder Shares at the price paid by the Sponsor (par value of $0.0001). Although these Founder Shares were purchased by the independent directors for value, under ASC 718, “Compensation – Stock Compensation,” these Founder Shares may be deemed stock-based compensation. The Company accounts for stock-based compensation expense in accordance with ASC 718, under which stock-based compensation associated with equity-classified awards is measured at fair value upon the grant date and recognized over the requisite service period. To the extent a stock-based award is subject to a performance condition, the amount of expense recorded in a given period, if any, reflects an assessment of the probability of achieving such performance condition, with compensation recognized once the event is deemed probable to occur. The fair value of equity awards has been estimated using a market approach. Forfeitures are recognized as incurred. As of October 6, 2021, the fair value of the 95,000 Founder Shares granted to certain independent directors by the Sponsor was $600,530 or $6.32 per share. The Company used a Monte Carlo Model simulation to arrive at the fair value of the stock compensation. The key assumptions in the option pricing model utilized are assumptions related to expected separation date of Units, anticipated business combination date, purchase price, share-price volatility, expected term, exercise date, risk-free interest rate and present value. The expected volatility as of the IPO closing date was derived based upon similar Special Purpose Acquisition Company (“SPAC”) warrants and technology exchange funds which with the Company’s stated industry target and terms until the exercise date. The Company’s Founder Shares sold to independent directors (see Note 5) was deemed within the scope of ASC 718 and are subject to a performance condition, namely the occurrence of a Business Combination. Compensation expense related to the 95,000 Founder Shares is recognized only when the performance condition is probable of occurrence, or more specifically when a Business Combination is consummated. Therefore, no stock-based compensation expense has been recognized for the three months ended March 31, 2023. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the Company’s financial statement. |
Summary of Significant Accoun_3
Summary of Significant Accounting Policies (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Summary of Significant Accounting Policies | |
Schedule of recognized Class A ordinary share subject to possible redemption | At March 31, 2023, the Class A ordinary shares subject to possible redemption reflected in the balance sheet is reconciled in the following table: Gross proceeds $ 250,000,000 Less: Proceeds allocated to Public Warrants (15,375,000) Class A ordinary share issuance costs (16,928,049) Plus: Accretion of carrying value to redemption value 37,303,049 Class A ordinary share subject to possible redemption as on December 31, 2021 255,000,000 Plus: Accretion of carrying value to redemption value 3,554,215 Class A ordinary share subject to possible redemption as on December 31, 2022 $ 258,554,215 Less : Redemption of ordinary shares (243,111,294) Plus: Accretion of carrying value to redemption value 733,104 Class A ordinary share subject to possible redemption as on March 31, 2023 $ 16,176,025 |
Schedule of reconciliation of the numerator and denominator used to compute basic and diluted net loss per share for each class of stock | For the three months ended March 31, 2023 Basic and diluted net income (loss) per share: Class A ordinary share Class B ordinary share Numerator: Allocation of net loss before accretion income $ (10,490) $ (13,999) Accretion of Class A ordinary shares to redemption value 733,104 — Net income (loss) including accretion of Class A Redeemable shares to redemption value $ 722,614 $ (13,999) Denominator: Weighted average shares outstanding 4,896,611 6,535,000 Basic and diluted net income (loss) per share $ 0.15 $ (0.00) For the three months ended March 31, 2022 Basic and diluted net income per share: Class A ordinary share Class B ordinary share Numerator: Allocation of net income before accretion income $ 2,276,393 $ 676,193 Accretion of Class A ordinary shares to redemption value — — Net income including accretion of Class A Redeemable shares to redemption value $ 2,276,393 $ 676,193 Denominator: Weighted average shares outstanding 22,000,000 6,535,000 Basic and diluted net income per share $ 0.10 $ 0.10 |
Fair Value Measurements (Tables
Fair Value Measurements (Tables) | 3 Months Ended |
Mar. 31, 2023 | |
Fair Value Measurements | |
Schedule of company's assets that are measured at fair value on a recurring basis | Quoted Significant Significant Prices Other Other in Active Observable Unobservable March 31, Markets Inputs Inputs Description 2023 (Level 1) (Level 2) (Level 3) Assets: Money Market Fund held in Trust Account $ 16,115,127 $ 16,115,127 — — Liabilities: Warrant Liability - Public Warrants $ 375,000 $ 375,000 — — Warrant Liability - Private Placement Warrants $ 17,100 — — $ 17,100 Quoted Significant Significant Prices Other Other in Active Observable Unobservable December 31, Markets Inputs Inputs Description 2022 (Level 1) (Level 2) (Level 3) Assets: Money Market Fund held in Trust Account $ 257,725,405 $ 257,725,405 — — Liabilities: Warrant Liability - Public Warrants $ 625,000 $ 625,000 — — Warrant Liability - Private Placement Warrants $ 28,500 — — $ 28,500 |
Schedule of quantitative information regarding Level 3 fair value measurements inputs | March 31, 2023 December 31, 2022 Share Price $ 10.60 $ 10.28 Exercise Price $ 11.50 $ 11.50 Term (years) 5.31 5.62 Volatility 5.3 % 4.10 % Risk Free Rate 3.53 % 3.90 % Dividend Yield 0.00 % 0.00 % |
Schedule of change in the fair value of the warrant liabilities | Private Placement Warrants Fair value as of December 31, 2022 $ 28,500 Change in fair value (11,400) Fair value as of March 31, 2023 $ 17,100 |
Description of Organization a_2
Description of Organization and Business Operations (Details) | 3 Months Ended | |||||||
Jan. 19, 2023 USD ($) | Oct. 22, 2021 USD ($) $ / shares shares | Mar. 31, 2023 USD ($) item $ / shares shares | Apr. 19, 2023 USD ($) | Jan. 31, 2023 USD ($) | Jan. 13, 2023 USD ($) $ / shares | Dec. 31, 2022 USD ($) $ / shares | Oct. 22, 2022 USD ($) | |
Description of Organization and Business Operations | ||||||||
Condition for future business combination number of businesses minimum | item | 1 | |||||||
Share price | $ / shares | $ 11.50 | $ 10.20 | ||||||
Sale of Private Placement Warrants (in shares) | shares | 13,070,000 | |||||||
Deferred underwriting fee payable | $ 13,100,000 | |||||||
Proceeds from Related Party Debt | $ 685,000 | |||||||
Condition for future business combination use of proceeds percentage | 80 | |||||||
Condition for future business combination threshold Percentage Ownership | 50 | |||||||
Condition for future business combination threshold Net Tangible Assets | $ 5,000,001 | |||||||
Redemption limit percentage without prior consent | 15 | |||||||
Obligation to redeem Public Shares if entity does not complete a Business Combination (as a percent) | 100% | |||||||
Redemption period upon closure | 10 days | |||||||
Maximum interest to dissolution expenses | $ 100,000 | |||||||
Cash held in operating bank account | 15,957 | $ 128,678 | ||||||
Marketable securities held in Trust Account | 16,115,127 | $ 257,725,405 | ||||||
Working capital deficit | 14,591,005 | |||||||
Interest income in trust account to pay tax obligations | $ 485,604 | |||||||
Threshold period to consummate business combination upon closing of IPO | 18 months | |||||||
Trust Amendment | ||||||||
Description of Organization and Business Operations | ||||||||
Initial extension period | 3 months | |||||||
Class A ordinary shares | ||||||||
Description of Organization and Business Operations | ||||||||
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | ||||||
Class A ordinary shares | Business Combination Agreement sponsor | ||||||||
Description of Organization and Business Operations | ||||||||
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | |||||||
Class B ordinary shares | ||||||||
Description of Organization and Business Operations | ||||||||
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | ||||||
Class B ordinary shares | Business Combination Agreement sponsor | ||||||||
Description of Organization and Business Operations | ||||||||
Ordinary shares, par value (in dollars per share) | $ / shares | 0.0001 | |||||||
Psyence Biomed | ||||||||
Description of Organization and Business Operations | ||||||||
Price per share before stock split | $ / shares | $ 10 | |||||||
Stock value before stock split | $ 50,000,000 | |||||||
If the consummation of a Business Combination by April 22, 2023 | ||||||||
Description of Organization and Business Operations | ||||||||
Period for consummation of business combination | 18 months | |||||||
If the consummation of a Business Combination by July 22, 2023 | ||||||||
Description of Organization and Business Operations | ||||||||
Period for consummation of business combination | 21 months | |||||||
Extension Period for consummation of business combination | 3 months | |||||||
If three month extension period | ||||||||
Description of Organization and Business Operations | ||||||||
Amount to be deposited in trust account | $ 247,500 | |||||||
Initial Public Offering | ||||||||
Description of Organization and Business Operations | ||||||||
Number of units issued | shares | 22,000,000 | 25,000,000 | ||||||
Share price | $ / shares | $ 10 | $ 10 | ||||||
Gross proceeds | $ 220,000,000 | |||||||
Deferred underwriting fee payable | $ 13,100,000 | $ 13,100,000 | ||||||
Offering costs | 15,937,545 | |||||||
Underwriting fees | 3,787,971 | |||||||
Deferred underwriting fee payable | $ 11,000,000 | |||||||
Other offering costs | 1,149,574 | |||||||
Net proceeds placed in trust account | $ 255,000,000 | |||||||
Share price | $ / shares | $ 10.20 | |||||||
Private Placement | Private placement warrants | ||||||||
Description of Organization and Business Operations | ||||||||
Proceeds from sale of Private Placement Warrants | $ 11,400,000 | |||||||
Sale of Private Placement Warrants (in shares) | shares | 1,140,000 | 1,080,000 | ||||||
Price of warrant | $ / shares | $ 10 | $ 10 | ||||||
Aggregate purchase price | $ 10,800,000 | |||||||
Over-allotment option | ||||||||
Description of Organization and Business Operations | ||||||||
Number of units issued | shares | 3,000,000 | 3,000,000 | ||||||
Gross proceeds | $ 30,000,000 | |||||||
Additional offering costs | 2,100,000 | |||||||
Over-allotment option | Private placement warrants | ||||||||
Description of Organization and Business Operations | ||||||||
Proceeds from sale of Private Placement Warrants | $ 600,000 | |||||||
Sponsor | Private placement warrants | ||||||||
Description of Organization and Business Operations | ||||||||
Sale of Private Placement Warrants (in shares) | shares | 60,000 | |||||||
Sponsor | Private Placement | Private placement warrants | ||||||||
Description of Organization and Business Operations | ||||||||
Sale of Private Placement Warrants (in shares) | shares | 920,000 | |||||||
Sponsor | Subsequent Event | ||||||||
Description of Organization and Business Operations | ||||||||
Marketable securities held in Trust Account | $ 82,500 |
Summary of Significant Accoun_4
Summary of Significant Accounting Policies (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||||
Jan. 06, 2023 | Oct. 06, 2021 | Mar. 31, 2023 | Dec. 31, 2022 | Jan. 31, 2023 | Oct. 22, 2021 | |
Summary of Significant Accounting Policies | ||||||
Unrecognized tax benefits | $ 0 | |||||
Unrecognized tax benefits accrued for interest and penalties | 0 | |||||
Number of shares redeemed | 23,497,468 | |||||
Provision for income taxes | 0 | |||||
Cash, FDIC insured amount | 250,000 | |||||
Cash, SIPC insured amount | $ 500,000 | |||||
Number of warrants to purchase shares issued | 13,070,000 | |||||
Share price | $ 10.20 | $ 11.50 | ||||
Anti dilutive securities excluded from computation of earnings per share amount | 13,070,000 | 13,070,000 | ||||
Class A ordinary shares subject to possible redemption | ||||||
Summary of Significant Accounting Policies | ||||||
Class A ordinary share subject to possible redemption, outstanding (in shares) | 1,502,532 | 1,502,532 | 25,000,000 | |||
Initial Public Offering | ||||||
Summary of Significant Accounting Policies | ||||||
Offering costs | $ 18,037,545 | |||||
Underwriting fees | 3,787,971 | |||||
Deferred underwriting fee payable | $ 11,000,000 | |||||
Other offering costs | $ 1,149,574 | |||||
Share price | $ 10 | $ 10 | ||||
Founder Shares | ||||||
Summary of Significant Accounting Policies | ||||||
Share price | $ 0.0001 | |||||
Founder Shares | Sponsor | ||||||
Summary of Significant Accounting Policies | ||||||
Number of shares granted | 95,000 | |||||
Fair value of shares granted | $ 600,530 | |||||
Granted shares, per share | $ 6.32 | |||||
Stock-based compensation expense | $ 0 |
Summary of Significant Accoun_5
Summary of Significant Accounting Policies - Reconciliation of class A ordinary shares subject to possible redemption reflected in the balance sheet (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||
Mar. 31, 2023 | Mar. 31, 2022 | Dec. 31, 2022 | Dec. 31, 2021 | |
Summary of Significant Accounting Policies | ||||
Less : Redemption of ordinary share | $ (243,111,294) | |||
Plus: Accretion of carrying value to redemption value | (733,104) | |||
Remeasurement of carrying value to redemption value | 733,104 | $ 1,253,516 | ||
Class A ordinary shares subject to possible redemption | ||||
Summary of Significant Accounting Policies | ||||
Gross proceeds | $ 250,000,000 | |||
Proceeds allocated to Public Warrants | (15,375,000) | |||
Class A ordinary share issuance costs | (16,928,049) | |||
Less : Redemption of ordinary share | (243,111,294) | |||
Plus: Accretion of carrying value to redemption value | 733,104 | $ 3,554,215 | 37,303,049 | |
Class A ordinary share subject to possible redemption | $ 16,176,025 | $ 258,554,215 | $ 255,000,000 |
Summary of Significant Accoun_6
Summary of Significant Accounting Policies - Reconciliation of the numerator and denominator used to compute basic and diluted net loss per share for each class of share (Details) - USD ($) | 3 Months Ended | |
Mar. 31, 2023 | Mar. 31, 2022 | |
Numerator: | ||
Accretion for Class A Ordinary shares to redemption value | $ 733,104 | |
Class A ordinary shares | ||
Numerator: | ||
Allocation of net income before accretion income | (10,490) | $ 2,276,393 |
Accretion for Class A Ordinary shares to redemption value | 733,104 | |
Net income including accretion of Class A Redeemable shares to redemption value | $ 722,614 | $ 2,276,393 |
Denominator: | ||
Weighted average shares outstanding, Basic | 4,896,611 | 22,000,000 |
Weighted average shares outstanding, Diluted | 4,896,611 | 22,000,000 |
Basic net income per share | $ 0.15 | $ 0.10 |
Diluted net income per share | $ 0.15 | $ 0.10 |
Class B ordinary shares | ||
Numerator: | ||
Allocation of net income before accretion income | $ (13,999) | $ 676,193 |
Net income including accretion of Class A Redeemable shares to redemption value | $ (13,999) | $ 676,193 |
Denominator: | ||
Weighted average shares outstanding, Basic | 6,535,000 | 6,535,000 |
Weighted average shares outstanding, Diluted | 6,535,000 | 6,535,000 |
Basic net income per share | $ 0 | $ 0.10 |
Diluted net income per share | $ 0 | $ 0.10 |
Initial Public Offering (Detail
Initial Public Offering (Details) - $ / shares | 3 Months Ended | |
Oct. 22, 2021 | Mar. 31, 2023 | |
Initial Public Offering | ||
Share price | $ 11.50 | $ 10.20 |
Initial Public Offering | ||
Initial Public Offering | ||
Number of units sold | 22,000,000 | 25,000,000 |
Share price | $ 10 | $ 10 |
Initial Public Offering | Public Warrants | ||
Initial Public Offering | ||
Number of shares in a unit | 1 | |
Number of warrants in a unit | 0.5 | |
Number of shares issuable per warrant | 1 | |
Exercise price of warrants | $ 11.50 | |
Over-allotment option | ||
Initial Public Offering | ||
Number of units sold | 3,000,000 | 3,000,000 |
Private Placement (Details)
Private Placement (Details) - USD ($) | Oct. 22, 2021 | Mar. 31, 2023 |
Private Placement | ||
Number of warrants to purchase shares issued | 13,070,000 | |
Private placement warrants | Sponsor | ||
Private Placement | ||
Number of warrants to purchase shares issued | 60,000 | |
Private Placement | Private placement warrants | ||
Private Placement | ||
Number of warrants to purchase shares issued | 1,140,000 | 1,080,000 |
Price of warrants | $ 10 | $ 10 |
Proceeds from private placement | $ 11,400,000 | |
Number of shares in a unit | 1 | |
Number of warrants in a unit | 0.5 | |
Number of shares per warrant | 1 | |
Exercise price of warrant | $ 11.50 | |
Private Placement | Private placement warrants | Sponsor | ||
Private Placement | ||
Number of warrants to purchase shares issued | 920,000 | |
Private Placement | Private placement warrants | Cantor | ||
Private Placement | ||
Number of warrants to purchase shares issued | 187,000 | |
Private Placement | Private placement warrants | CCM | ||
Private Placement | ||
Number of warrants to purchase shares issued | 33,000 |
Related-Party Transactions- Fou
Related-Party Transactions- Founder Shares (Details) | 1 Months Ended | ||||
Oct. 19, 2021 shares | Mar. 11, 2021 USD ($) D $ / shares shares | Sep. 30, 2021 shares | Mar. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2022 $ / shares shares | |
Related-Party Transactions | |||||
Outstanding balance of related party note | $ | $ 0 | ||||
Loan from Sponsor | $ | $ 685,000 | ||||
Class B ordinary shares | |||||
Related-Party Transactions | |||||
Ordinary shares, par value, (per share) | $ / shares | $ 0.0001 | $ 0.0001 | |||
Ordinary shares, shares outstanding | 6,535,000 | 6,535,000 | |||
Founder Shares | |||||
Related-Party Transactions | |||||
Number of shares forfeited | 841,500 | ||||
Founder Shares | Class B ordinary shares | |||||
Related-Party Transactions | |||||
Share dividend | 0.099 | ||||
Ordinary shares, shares outstanding | 6,611,500 | ||||
Founder Shares | Sponsor | |||||
Related-Party Transactions | |||||
Number of shares forfeited | 76,500 | ||||
Founder Shares | Sponsor | Class B ordinary shares | |||||
Related-Party Transactions | |||||
Aggregate purchase price | $ | $ 25,000 | ||||
Number of shares issued | 5,912,500 | ||||
Ordinary shares, par value, (per share) | $ / shares | $ 0.0001 | ||||
Share dividend | 0.017 | ||||
Ordinary shares, shares outstanding | 6,015,000 | ||||
Restrictions on transfer period of time after business combination completion | 1 year | ||||
Stock price trigger to transfer, assign or sell any shares or warrants of the company, after the completion of the initial business combination (in dollars per share) | $ / shares | $ 12 | ||||
Threshold trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D | 20 | ||||
Threshold consecutive trading days for transfer, assign or sale of shares or warrants, after the completion of the initial business combination | D | 30 | ||||
Threshold period after the business combination in which the 20 trading days within any 30 trading day period commences | 150 days |
Related-Party Transactions - Ad
Related-Party Transactions - Additional Information (Details) - USD ($) | 3 Months Ended | 12 Months Ended | ||||
Jun. 21, 2021 | Mar. 31, 2023 | Dec. 31, 2022 | Jun. 06, 2023 | Jan. 17, 2023 | Mar. 11, 2021 | |
2023 Note | Sponsor | ||||||
Related-Party Transactions | ||||||
Conversion Price | $ 10 | |||||
Extension funding of sponsor loan deposited into bank account | $ 437,500 | |||||
Promissory Note with Related Party | ||||||
Related-Party Transactions | ||||||
Maximum borrowing capacity of related party promissory note | $ 300,000 | |||||
Repayment of promissory note - related party | $ 1,000,000 | |||||
Promissory Note with Related Party | Extension Loan | Sponsor | ||||||
Related-Party Transactions | ||||||
Long term debt | $ 247,500 | |||||
Promissory Note with Related Party | Extension Loan | Sponsor | Maximum | ||||||
Related-Party Transactions | ||||||
Amount of debt issued | $ 495,000 | |||||
Promissory Note with Related Party | 2023 Note | ||||||
Related-Party Transactions | ||||||
Amount of debt issued | $ 1,000,000 | |||||
Promissory Note with Related Party | 2023 Note | Sponsor | Maximum | ||||||
Related-Party Transactions | ||||||
Amount of debt issued | $ 1,000,000 | |||||
Related Party Loans | ||||||
Related-Party Transactions | ||||||
Loan conversion agreement warrant | 1,500,000 | |||||
Outstanding working capital loans | $ 0 | |||||
Related Party Loans | Working capital loans warrant | ||||||
Related-Party Transactions | ||||||
Price of warrant | $ 10 | |||||
Support Services | ||||||
Related-Party Transactions | ||||||
Expenses per month | $ 30,000 | |||||
Expenses incurred and paid | 60,000 | $ 220,000 | ||||
Due to related party | 70,000 | $ 100,000 | ||||
Aggregate proceeds paid | $ 32,755 |
Commitments and Contingencies (
Commitments and Contingencies (Details) - USD ($) | 3 Months Ended | |
Oct. 22, 2021 | Mar. 31, 2023 | |
Commitments and Contingencies | ||
Underwriting cash discount per unit | $ 0.20 | |
Additional advisor and expenses | $ 612,029 | |
Underwriter cash discount | $ 3,787,971 | |
Deferred underwriting commission per unit | $ 0.50 | |
Deferred underwriting fee payable | $ 13,100,000 | |
Deferred underwriting commission | $ 12,500,000 | |
Over-allotment option | ||
Commitments and Contingencies | ||
Options to granted number of days to underwriters | 45 days | |
Number of units issued | 3,000,000 | 3,000,000 |
Additional deferred underwriting cash discount per unit | $ 0.20 | |
Additional deferred underwriting cash discount | $ 600,000 | |
Over-allotment option | Maximum | ||
Commitments and Contingencies | ||
Number of units issued | 3,300,000 |
Shareholders' Deficit - Ordinar
Shareholders' Deficit - Ordinary shares (Details) | 3 Months Ended | ||
Mar. 31, 2023 Vote $ / shares shares | Jan. 06, 2023 shares | Dec. 31, 2022 $ / shares shares | |
Class A ordinary shares | |||
Shareholders' Equity (Deficit) | |||
Ordinary shares, shares authorized | 100,000,000 | 100,000,000 | |
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | |
Class A ordinary shares subject to possible redemption | |||
Shareholders' Equity (Deficit) | |||
Class A ordinary share subject to possible redemption, outstanding (in shares) | 1,502,532 | 1,502,532 | 25,000,000 |
Class A ordinary shares not subject to possible redemption | |||
Shareholders' Equity (Deficit) | |||
Ordinary shares, shares issued | 1,140,000 | 1,140,000 | |
Ordinary shares, shares outstanding | 1,140,000 | 1,140,000 | |
Class B ordinary shares | |||
Shareholders' Equity (Deficit) | |||
Ordinary shares, shares authorized | 10,000,000 | 10,000,000 | |
Ordinary shares, par value (in dollars per share) | $ / shares | $ 0.0001 | $ 0.0001 | |
Ordinary shares, shares issued | 6,535,000 | 6,535,000 | |
Ordinary shares, shares outstanding | 6,535,000 | 6,535,000 | |
Ordinary shares, votes per share | Vote | 1 | ||
Shares subject to forfeiture | 76,500 | ||
Underwriters over allotment period | 45 days | ||
Conversion of stock, shares issued | 1 | ||
Ratio to be applied to the stock in the conversion | 22.74 |
Shareholders' Deficit - Preferr
Shareholders' Deficit - Preferred Shares (Details) - shares | Mar. 31, 2023 | Dec. 31, 2022 |
Shareholders' Deficit | ||
Preference shares, shares authorized | 1,000,000 | 1,000,000 |
Preference shares, shares issued | 0 | 0 |
Preference shares, shares outstanding | 0 | 0 |
Shareholders' Deficit - Warrant
Shareholders' Deficit - Warrants (Details) | 3 Months Ended |
Mar. 31, 2023 D $ / shares | |
Derivative Warrant Liabilities | |
Trading period after business combination used to measure dilution of warrant | D | 20 |
Public Warrants | |
Derivative Warrant Liabilities | |
Warrant exercise period condition one | 30 days |
Warrant exercise period condition two | 12 months |
Public Warrants expiration term | 5 years |
Share price trigger used to measure dilution of warrant | $ 9.20 |
Percentage of gross new proceeds to total equity proceeds used to measure dilution of warrant | 60 |
Warrant exercise price adjustment multiple | 115 |
Public Warrants | Redemption of warrants when the price per Class A ordinary share equals or exceeds $18.00 | |
Derivative Warrant Liabilities | |
Redemption price per public warrant (in dollars per share) | $ 0.01 |
Redemption period | 30 days |
Warrant redemption condition minimum share price | $ 18 |
Threshold trading days for redemption of public warrants | 20 days |
Threshold consecutive trading days for redemption of public warrants | D | 30 |
Fair Value Measurements (Detail
Fair Value Measurements (Details) - USD ($) | Mar. 31, 2023 | Dec. 31, 2022 |
Assets: | ||
Money Market Fund held in Trust Account | $ 16,115,127 | $ 257,725,405 |
Liabilities: | ||
Warrants outstanding | 13,070,000 | 13,070,000 |
Quoted Prices in Active Markets (Level 1) | ||
Assets: | ||
Money Market Fund held in Trust Account | $ 16,115,127 | $ 257,725,405 |
Public Warrants | ||
Liabilities: | ||
Warrant Liability | $ 375,000 | $ 625,000 |
Warrants outstanding | 12,500,000 | 12,500,000 |
Public Warrants | Quoted Prices in Active Markets (Level 1) | ||
Liabilities: | ||
Warrant Liability | $ 375,000 | $ 625,000 |
Private Placement Warrants | ||
Liabilities: | ||
Warrant Liability | $ 17,100 | $ 28,500 |
Warrants outstanding | 570,000 | 570,000 |
Private Placement Warrants | Significant Other Unobservable Inputs (Level 3) | ||
Liabilities: | ||
Warrant Liability | $ 17,100 | $ 28,500 |
Fair Value Measurements - Level
Fair Value Measurements - Level 3 Fair Value Measurements Inputs (Details) | Mar. 31, 2023 item $ / shares Y | Dec. 31, 2022 item Y $ / shares |
Public Warrants and Private Placement Warrants | ||
Level 3 Fair Value Measurements Inputs | ||
Exercise price of warrants | $ / shares | $ 0.03 | $ 0.05 |
Share Price | Significant Other Unobservable Inputs (Level 3) | ||
Level 3 Fair Value Measurements Inputs | ||
Warrants, measurement input | $ / shares | 10.60 | 10.28 |
Exercise Price | Significant Other Unobservable Inputs (Level 3) | ||
Level 3 Fair Value Measurements Inputs | ||
Warrants, measurement input | $ / shares | 11.50 | 11.50 |
Term (years) | Significant Other Unobservable Inputs (Level 3) | ||
Level 3 Fair Value Measurements Inputs | ||
Warrants, measurement input | Y | 5.31 | 5.62 |
Volatility | Significant Other Unobservable Inputs (Level 3) | ||
Level 3 Fair Value Measurements Inputs | ||
Warrants, measurement input | item | 0.053 | 0.0410 |
Risk Free Rate | Significant Other Unobservable Inputs (Level 3) | ||
Level 3 Fair Value Measurements Inputs | ||
Warrants, measurement input | item | 0.0353 | 0.0390 |
Dividend Yield | Significant Other Unobservable Inputs (Level 3) | ||
Level 3 Fair Value Measurements Inputs | ||
Warrants, measurement input | item | 0 | 0 |
Fair Value Measurements - Chang
Fair Value Measurements - Change in the Fair Value of the Warrant Liabilities (Details) | 3 Months Ended |
Mar. 31, 2023 USD ($) | |
Fair Value Measurements | |
Fair value liabilities transfer into level 3 | $ 0 |
Fair value liabilities transfer out of level 3 | 0 |
Significant Other Unobservable Inputs (Level 3) | Private placement warrants | |
Fair Value Measurements | |
Fair value of warrant liabilities at the beginning | 28,500 |
Change in fair value | (11,400) |
Fair value of warrant liabilities at end | $ 17,100 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) | Apr. 19, 2023 | Mar. 31, 2023 | Dec. 31, 2022 |
Subsequent Event [Line Items] | |||
Investments held in Trust Account | $ 16,115,127 | $ 257,725,405 | |
Subsequent Event [Member] | Sponsor | |||
Subsequent Event [Line Items] | |||
Investments held in Trust Account | $ 82,500 |